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Low gene transfer efficiency in blood vessels is still a significant problem
Various types of catheters are available for gene transfer into the vessel wall. 1, 2 Unfortunately, even with powerful viral vectors gene transfer efficiency through human atherosclerotic lesions and lipid-rich atheroma is Յ5%, and results in a potentially harmful biodistribution of the vector. 3 Therefore, there is great interest in developing better strategies for efficient, targeted gene delivery into the vessel wall. Accordingly several biologic targeting systems have recently been introduced. [4] [5] [6] [7] [8] [9] [10] In spite of relatively low transfection efficiency adenoviruses are still the most widely used viral vectors for vascular applications since they can transfect both proliferating and non-proliferating cells. 2, 11 However, adenoviruses also transfect many unwanted organs and peripheral blood monocytes. 3 Therefore, novel methods to target adeno- viruses to the vessel wall have been developed. 6, 9, 10, 12, 13 These include matrix metalloproteinase-2 and -9 (MMP-2 and -9) targeted tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) encoding adenoviruses, 10 ␣ integrin targeted human interleukin-2 encoding adenoviruses 14 and endothelial cell targeted adenoviruses. 9 However, longer expression times are probably needed for better clinical efficacy. Thus, adeno-associated viruses (AAV) have been successfully used to transduce rabbit jugular veins with expression lasting beyond 30 days, 15 and a method to target AAV gene therapy to vascular endothelial cells has been described. 8 Furthermore, modified retrovirus, Semliki Forest virus, Baculovirus and herpes simplex virus vectors have been used for vascular gene transfer in vivo, but these vectors have not yet solved all problems related to vascular gene transfer. 7, [16] [17] [18] The most widely used non-viral vector for vascular gene therapy is plasmid DNA with or without carrier molecules. Due to the safety aspects and relatively easy processibility, there is a great interest in the development of targeted non-viral gene delivery methods. However, relatively low tranfection efficiency has limited their use in vascular applications. It should be pointed out that different treatments strategies require different gene transfer efficiencies, eg with secreted compounds, such as growth factors or NO, even a relatively inefficient vector may be useful, whereas antisense or decoy constructs for cell cycle mediators need to be delivered in the majority of vascular cells before a therapeutic effect can be expected.
Therapeutic ultrasound has also proven efficient in augmenting intravascular gene delivery. 19 For the treatment of in-stent restenosis a good method to deliver vectors locally to the target area is the stent itself. Klugherz et al succeeded in transducing porcine coronary arteries with a plasmid DNA eluting polymer-coated stent. 20 Also, they reported approximately 6% transfection efficiency using a stent-based antibody-tethered adenoviral gene transfer system. 21 An ex vivo approach using genetically engineered cells attached to the stent surface could be another possibility to achieve long-term transgene expression. Panetta et al have demonstrated GFP expression 1 month after implantation of a stent carrying engineered autologous smooth muscle cells (SMCs) into porcine coronary artery. 22 However, these approaches still suffer from fast wash-out of the vectors from the stent coating and detachment of the seeded cells from the stent struts.
Identification of new treatment genes has provided more opportunities for therapy
Smooth muscle cell migration and proliferation are key factors in the development of restenosis, in-stent restenosis and vein graft stenosis 23 and most gene therapy strategies are directed towards these targets (Table 1) . Early markers of SMC activation, such as oncogenes are detectable shortly after arterial injury. Antisense oligonucleotides directed against oncogenes and cell cycle regulators have been used to decrease neointimal thickening in animal models. Promising results have been obtained with antisense oligonucleotides against NFB, 24 E2F 25 and cmyc. 26 Also, adenoviral Gax (growth arrest homeobox) gene transfer has been shown to reduce neointimal hyperplasia in stented rabbit iliac arteries. 27 The plateletderived growth factor (PDGF) gene family is one of the most potent chemoattractants of vascular SMC. PDGFs mediate neointimal growth after vascular injury and this can be prevented by inhibition of PDGF expression with antibodies against PDGF or its receptors. 28 However, clinical use of antibodies carries the risk of immunoreactivity and thus gene-based approaches against PDGFs have been introduced. 29 MMPs are also important effectors in the migration of SMCs and can be inhibited by overexpressing tissue inhibitors of metalloproteinases (TIMPs). Gene transfer of TIMP-1 has been shown to reduce neointimal growth in rat and rabbit denudation models. 10 Since intravascular manipulation causes damage to endothelium, it is hypothesized that rapid re-endothelialization of arterial wall after balloon dilatation should reduce restenosis. Members of the vascular endothelial growth factor (VEGF) family induce endothelial cell proliferation and migration. Hiltunen et al demonstrated that both VEGF-A and VEGF-C gene therapy reduced restenosis after arterial injury. 30 Also, gene therapy with VEGF-D attenuates neointimal growth in rabbits. 31 In addition to re-endothelization, the effects of VEGFs may be at least partially due to increased nitric oxide (NO) production which inhibits SMC migration and proliferation. Hepatocyte growth factor (HGF) is another gene that is reported to reduce neointimal hyperplasia through re-endothelization and increased NO production. 32 Aiming at increased NO production Janssens et al have previously shown that eNOS gene transfer reduced neointima formation in a rat model and Varenne et al noticed the same effect with eNOS gene transfer in a pig model. Also, van der Leyen et al have achieved prevention of restenosis with iNOS gene transfer. Further, extracellular superoxide dismutase (EC-SOD) gene transfer has been shown to reduce neointima formation in a rabbit model. 33 Platelet-activating factor (PAF)-like phospholipids are characteristic of proinflammatory conditions. These phospholipids are inactivated by PAF-acetylhydrolase (PAF-AH). Quarck et al showed that PAF-AH prevents neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. 34 It has also recently been demonstrated that a therapeutic effect on intimal hyperplasia can be achieved by inhibiting tissue factor (TF) with TF pathway inhibitor (TFPI). [35] [36] [37] Genes that have an effect on various pathological processes in the vessel wall, such as VEGFs, HGF or E2F decoy may offer the most promising tools for gene therapy against post-intervention vessel occlusion. On the other hand, similar effects may be achieved with combination therapy.
Combination therapy may be more efficient than single gene treatment and first evidence of prolonged therapeutic effect has been achieved
The majority of gene therapy studies for restenosis, instent restenosis and vein graft stenosis have evaluated only single genes. Considering the complex pathophysiology of these events it is possible that combination therapy or 'gene cocktails' may provide a better treatment effect. Thus, utilization of different mechanisms which are known to reduce restenosis may lead to an additive treatment effect. So far, there have been only a few reports on combination therapy and its effects on these remodeling processes. Puhakka et al studied peptide retargeted TIMP-1 plus VEGF-C combination gene therapy in a rabbit model and found a prolonged treatment effect. 38 Leppänen et al have shown that combination of VEGF-C gene transfer and treatment with PDGF receptor kinase inhibitor STI571 leads to a long-term reduction in neointima formation in a balloon-denuded rabbit aorta. 39 These studies have shown prolonged therapeutic effect compared with single treatment with VEGF-C or STI571. 28, 30 As another example of combination therapy Atsuchi et al reduced neointima formation in a rabbit Gene Therapy model by brief irrigation with tissue factor pathway inhibitor (TFPI) combined with adenovirus-mediated local TFPI gene transfer. 37 
Inhibition of vein graft stenosis using gene therapy has been successful in animal models
Surgical approach provides an opportunity to use ex vivo approach, which allows longer contact time with vector and may result in a better gene transfer efficiency. After surgical revascularization vein grafts are exposed to high blood pressure, which causes endothelial cell damage, platelet and leukocyte adhesion, thrombosis, matrix destruction and SMC proliferation. Although neointimal hyperplasia caused by SMC proliferation and migration may not be the most prominent factors producing significant stenosis, it exposes veins to the later development of graft atheroma. Vein graft stenosis has similar features to neointimal hyperplasia in arteries, and thus the same therapeutic approaches may apply. Suppressing SMC migration and proliferation by inhibiting MMPs with TIMP-1, TIMP-2 or TIMP-3 40 has been shown to inhibit neointima formation. TIMP-2 reduces neointima formation in human saphenous veins and TIMP-3 decreased stenosis in human and porcine veins. 40 Also, long-term stabilization of the vein grafts with ex vivo pressure-mediated E2F decoy oligonucleotide gene transfer has been achieved. 41 Endothelial damage predisposes vein grafts to thrombus formation and stimulates SMC migration to intima. Thus, re-endothelization of the graft should be useful. Ohno et al demonstrated accelerated reendothelization with suppressed thrombogenesis and neointimal hyperplasia using gene transfer of C-type natriuretic peptide (CNP). 42 An emerging new area of gene therapy is prevention of stenosis in dialysis access grafts and arterio-venous loops.
Clinical trials have indicated cautious optimism only in vein graft stenosis
In spite of promising results achieved in preclinical animal models, only a few clinical trials have been started (Table 2 ). To date, there are only two successful reports on the prevention of neointimal hyperplasia in clinical trials. Previously, Mann et al reduced bypass vein graft failure rate with E2F antisense decoy by using an ex vivo gene transfer method and Grube et al have now reported significant efficacy of the same construct in coronary vein grafts. 43 Laitinen et al demonstrated the safety and feasibility of intravascular catheter-mediated VEGF-A plasmid/liposome gene transfer to human coronaries in conjunction with PTCA in a randomized, controlled phase I study, but no efficacy was detected in control angiography. 1 In a randomized, controlled phase II study of catheter-mediated VEGF-A gene transfer with plasmid/liposome or adenovirus to infrainguinal arteries after PTA, increased vessel formation was seen in the VEGF treatment groups in the follow-up angiography 3 months after the gene transfer, but no effect was found on restenosis. 44 The first anti-sense-based clinical study for in-stent restenosis was recently published by Kutryk et al. 45 They used antisense oligonucleotides against cmyc to inhibit cell proliferation in stented lesions. Although the pre-clinical results in preventing intimal hyperplasia with this cell cycle regulator were very promising, the study did not show any therapeutic effect measured by intravascular ultrasound and angiography. 45 This may be explained by compromised efficacy of intravascular delivery compared with ex vivo approach used for vein graft stenosis. Thus, vascular gene therapy still faces the same problem as any pharmacological therapy: how to transfer positive pre-clinical results to clinically successful therapy.
Summary
Gene therapy offers an alternative approach for the treatment of vessel remodelling. First clinical trials have established the safety of gene therapy for the treatment of these remodeling processes and some positive clinical results have been reported for vein graft stenosis. Currently several genes and proteins have shown promising results in pre-clinical studies. However, randomized, double-blinded, placebo-controlled phase II/III studies are needed to determine usefulness of gene therapy for these diseases.
